Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)
Sponsor: Nuvalent Inc.
A PHASE3 clinical study on Anaplastic Lymphoma Kinase-positive and Non-small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Nuvalent Inc. and has accumulated 9 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nuvalent Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alcabideche, Portugal , Amsterdam, Netherlands , Ancona, Italy , Angers, France , Athens, Greece , Atlanta, United States , Bangkok, Thailand , Barcelona, Spain , Bari, Italy and 89 more locations